Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

10x Genomics (NASDAQ:TXG) just reported results for the first quarter of 2024. 10x Genomics reported earnings per share of -50 cents. This met the analyst estimate for EPS of -50 cents.

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158. ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period. There have been no specific sales or ...

Short interest in 10x Genomics Inc (NASDAQ:TXG) increased during the last reporting period, rising from 6.60M to 7.61M. This put 8.23% of the company's publicly available shares short. Short ...

View 10x Genomics, Inc. (TXG) current and estimated P/E ratio data provided by Seeking Alpha.